Diligence memo · auto-generated · as of July 2, 2026

DuraStat LLC

DuraStat LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

DuraStat LLC operates in Other Health Care, based in WAYNE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

DuraStat LLC has raised $6.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $4.5M on 2019-03-15.

Most recent recorded round closed around 2022-01-17.

Valuation (modeled)modeled

Provath models DuraStat LLC at approximately $27M (range $3.0M–$104M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.74× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era. Within the normal band (74% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 34 months.

Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.9× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 70% of Other Health Care peers (5377 compared).

Modeled value ranks above 55% of those peers.

Closest niche peers: CareHarmony, Inc., Dragonfly Endoscopy Inc., NuvoAir Holdings, Inc., Post Acute Recovery, Inc., Micro Interventional Devices, Inc..

Peoplefiled

9 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.